DISTRIBUTION SERVICES AND STORAGE AGREEMENT BETWEEN CELGENE CORPORATION AND SHARP CORPORATION

                                                                   EXHIBIT 10.53

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the  information  subject to the  confidentiality  request.
Omissions  are  designated  as ***. A complete  version of this exhibit has been
filed separately with the Securities and Exchange Commission.



                   DISTRIBUTION SERVICES AND STORAGE AGREEMENT

                                     BETWEEN

                               CELGENE CORPORATION

                                       AND

                                SHARP CORPORATION

                                 JANUARY 1, 2005

                                       1

*** - indicates  material omitted pursuant to a Confidential  Treatment  Request
and filed separately with the Securities and Exchange Commission.


<PAGE>


                   DISTRIBUTION SERVICES AND STORAGE AGREEMENT

         This Amended and Restated  Distribution Services Agreement entered into
this 1st day of January,  2005, by and between Celgene  Corporation,  a Delaware
corporation ("CELGENE"), and Sharp Corporation ("SHARP").

         WHEREAS,  CELGENE  and  SHARP  entered  into  a  Distribution  Services
Agreement dated June 12, 2000 (the "Agreement"); and

         WHEREAS, CELGENE and SHARP desire to amend and restate the Agreement in
its entirety.

         NOW, THEREFORE, in consideration of the promises, covenants, agreements
and other  valuable  consideration  hereinafter  set forth,  the parties  hereto
hereby amend and restate the Agreement in its entirety as follows:

Article 1.      DEFINITIONS

         As used in this  agreement,  the following words and phrases shall have
the following meanings:

                  (a)      "FDA"  shall  mean the  United  States  Food and Drug
                           Administration, or any successor entity thereto.

                  (b)      "Act"  shall mean the United  States  Food,  Drug and
                           Cosmetics Act, as amended,  and rules and regulations
                           promulgated thereunder.

                  (c)      "Products" are defined in schedule 1.(c)

                  (d)      "SHARP  facility" shall mean SHARP's  facility either
                           owned or  leased by Sharp,  at which  SHARP  provides
                           distribution services for pharmaceutical products.

                  (e)      "API" shall mean the active pharmaceutical ingredient
                           required  to   manufacture  a  formulation   of  drug
                           product.

                  (f)      "One Time Costs" as defined in schedule 1.(f)

Article 2.      TERM

         This  Agreement  shall be in effect  for an  initial  term of *** years
         commencing January 1st, 2005 (the "Initial Term"), for the distribution
         of Celgene products,  if not earlier terminated  according to Article 5
         of this Agreement. The term of this Agreement shall automatically renew
         for  successive  ***-year  periods unless either party hereto gives the

                                       2

*** - indicates  material omitted pursuant to a Confidential  Treatment  Request
and filed separately with the Securities and Exchange Commission.


<PAGE>


         other  notice of  non-renewal  hereof at least *** months  prior to the
         expiration of the Initial Term or any *** year renewal  period,  as the
         case may be.  Distribution terms of in-licensed  product are subject to
         the term of the individual licensing agreements.

Article 3.      ENGAGEMENT; SERVICES

3.01     CELGENE hereby engages SHARP and SHARP hereby accepts the engagement by
         CELGENE,  to provide the services  hereinafter  described on the terms,
         and subject to the conditions set forth in this Agreement.

3.02     SHARP  will,  as  agent  for  CELGENE,  process  sales  orders  for the
         Products,  ship the  Products  and  process  returns  of the  Products.
         Without limiting the generality of the preceding sentence, SHARP will

                  (a)      dedicate  at  least  ***  square  feet  at the  SHARP
                           facility for the  warehousing  of the  Products,  the
                           processing  of sales  orders for the Products and the
                           processing of returns of the Products;

                  (b)      dedicate at least ***  full-time  SHARP  employees to
                           provide the services described herein;

                  (c)      provide  storage space at the SHARP facility to store
                           API as needed;

                  (d)      provide  perpetual   tracking  of  inventory  of  the
                           Products by lot number.

                  (e)      provide  supervision  of the  destruction of returned
                           and  expired  Products;  and  provide  reporting  and
                           documentation  of  product   destruction  within  ten
                           business days of destruction of product.

                  (f)      provide for the  refrigerated,          2-8(degrees)C
                           (36-46(degrees)F), storage as required.

                  (g)      provide   office  space  for  at  least  ***  Celgene
                           employee.

3.03     CELGENE will provide SHARP remote access to CELGENE's  validated  sales
         order processing  system, and the computer equipment to be described on
         Schedule 3.03 hereto for the purpose of such access and to enable SHARP
         to report on a daily work-day basis to CELGENE. SHARP acknowledges that
         any and all information equipment, inventory or other items provided to
         SHARP  pursuant  to this  Agreement  shall be and remain the  exclusive
         property of CELGENE,  shall be used by SHARP  solely for the purpose of
         rendering  the services  provided for  hereunder  and shall be returned
         promptly  by SHARP  to  CELGENE  upon  termination  of this  Agreement,
         without SHARP having retained any copy thereof.

Article  4.     FEES, EXPENSES

                                       3

*** - indicates  material omitted pursuant to a Confidential  Treatment  Request
and filed separately with the Securities and Exchange Commission.


<PAGE>


4.01     For all services to be rendered by SHARP to CELGENE hereunder,  CELGENE
         shall pay SHARP the fees set forth on Schedule 4.01 hereto at the times
         also described in such Schedule.

4.02     Freight charges will be billed directly to CELGENE by carriers.

4.03     Additional  charges due to volume demand,  changes required by Celgene,
         and/or annual  inflation/wage  increases,  to be mutually  agreed upon.
         Reductions in charges due to volume  decline or other similar  factors,
         are to be  negotiated  in good faith and mutually  agreed upon.  If the
         parties cannot agree on the price  adjustments,  the parties will abide
         by the opinion of a mutually agreed upon arbitrator.

5.       TERMINATION

5.01     Upon the occurrence of the following events, either party may terminate
         this Agreement by giving the other party *** days prior written notice:

                  (a) If the other  party is unable  to pay its  debts,  becomes
                  bankrupt  or  insolvent  or enters  into  liquidation  whether
                  compulsory  or  voluntary,  or  compounds  with or  convenes a
                  meeting of its creditors,  or has a receiver appointed overall
                  or part of its assets,  or takes or suffers any similar action
                  in consequence of a debt, or ceases for any reason to carry on
                  business; or

                  (b)  Upon  the  breach  of  any  material  provision  of  this
                  Agreement by the other party if the breach is not cured within
                  *** days after written  notice thereof to the party in default
                  and the  material  breach  continues  to  exist at the time of
                  notice of termination.

5.02     CELGENE may  terminate  this  Agreement  at any time by giving *** days
         written notice to SHARP, if CELGENE, in its sole discretion, determines
         that it will no longer  market  the  Products  or if the FDA  withdraws
         approval of the  manufacture or marketing of the Products.  CELGENE may
         terminate this agreement if the FDA or any other regulatory agency that
         regulates  the  Products  takes any  action  the  result of which is to
         prohibit  the  manufacture,  sale or use or any  similar  action of the
         Products or any raw material contained therein or to impose significant
         restriction.

5.03     The Agreement may be terminated  Pursuant to Article 2, which  provides
         for  termination,  by notice from either party,  upon expiration of the
         Initial Term or any *** period.

5.04     Termination,  expiration, or cancellation of this Agreement through any
         means  and  for  any  reason  shall  not  relieve  th